M&A / Deals Gilead Sciences completes Tubulis acquisition for $5bn Pharmaceutical TechnologyGilead Sciences has concluded its acquisition of Germany-based biotechnology company Tubulis in a transaction valued at up to $5bn.Read full story pharminent May 22, 2026 (Last updated: May 22, 2026) Pharmaceutical Technology Gilead Sciences has concluded its acquisition of Germany-based biotechnology company Tubulis in a transaction valued at up to $5bn. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: In Alzheimer’s, Bristol Myers sees big promise beyond amyloidNext: GBL joins CVC in 10.7bn takeover bid for Recordati Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
